For most specialties, that's an annoying but manageable problem. For infectious disease practices, it's bigger. You're managing prolonged antimicrobial courses, OPAT coordination, infusion administration, and specialty drugs that often cost more than the visit itself. One denied drug claim can wipe out a month of office-visit revenue.
This article breaks down what an AR denial actually is, the denial scenarios that show up most often in ID billing, and a practical framework for fixing, appealing, and preventing them before they pile up in your receivables.
Key Takeaways
- AR denials are unpaid or underpaid claims requiring investigation, correction, or appeal
- Eligibility gaps, authorization lapses, coding mismatches, and necessity disputes drive most ID denials
- OPAT and infusion claims involve multiple components that must align in dates, units, and locations
- Hard denials on buy-and-bill drugs are realized losses, not deferred revenue
- Track denials by dollar value and root cause, not just claim count
What Is an A/R Denial and Why Does It Matter?
Accounts receivable, or AR, is every dollar owed to your practice for services already rendered. A claim lands in AR the moment you bill it and stays there until it's paid, adjusted, or written off.
An AR denial is a payer's decision, made after reviewing the claim, that it won't pay as billed. That's different from a front-end rejection, which happens before the payer even reviews the claim, usually because of a data or format error caught by a clearinghouse edit.
According to CMS's claims guidance, rejections and denials are handled through separate processes. Treating them the same way wastes staff time chasing the wrong fix.
Once a claim is denied, it needs one of a few things:
- A corrected claim, if the underlying data was wrong
- Reconsideration or appeal, if the claim was accurate but needs supporting evidence
- Medical record submission, if the payer requested documentation
- Patient-balance review, if responsibility was misassigned
Why Unresolved Denials Cost More Than the Claim Value
A denial sitting in AR isn't just a missing payment. It's staff hours spent researching the claim, delayed cash flow while the drug or administration cost has already been paid out of pocket, and, if it keeps happening, a sign that something upstream in your workflow is broken.
Here's a concrete example. A six-week OPAT course can carry roughly $264 in coordination costs alone (authorization follow-up, lab chasing, weekly review prep), representing close to 14% of that course's total margin before a single denial happens. If the drug claim then denies, that margin evaporates entirely.
Before assuming a denial is a coding error, check it against the actual remittance advice, the specific denial code, your contract terms, and current payer policy. Don't assume industry-wide denial benchmarks apply to your practice — use your own claim volume, payer mix, and service-line economics instead.
Common A/R Denial Scenarios in Infectious Disease Billing
These aren't fixed payer rules. They're recurring root-cause categories that show up across payers, plans, and services, though the specific requirements always vary by plan and place of service.
Eligibility, Coverage, and Coordination-of-Benefits Denials
Coverage problems are often invisible until the denial arrives. Common triggers include:
- Inactive coverage on the date of service
- Incorrect subscriber or member details
- Secondary-payer sequencing errors (wrong payer billed first)
- Coverage exclusions specific to the plan
- A mismatch between the billed provider and the payer's enrollment record
Picture an infusion claim submitted three weeks after a patient's employer changed insurance carriers mid-course. Nobody re-verified eligibility between visits, so the claim goes to the old payer and bounces back denied.
Front-end controls worth reviewing: eligibility date, plan benefits, subscriber information, payer ID, provider enrollment status, referral requirements, and coordination-of-benefits status.
CMS's eligibility guidance notes that eligibility responses include Medicare Advantage and MSP (Medicare Secondary Payer) information that should be checked before, not after, the infusion runs.
Authorization, Referral, and Medical-Necessity Denials
This is the category that hits hardest in infectious disease billing, largely because treatment courses run long and authorizations don't always run with them.
An initial authorization covers a defined duration. If reauthorization isn't filed before that window closes, therapy can continue into a coverage gap, and the denial often doesn't surface until weeks of drug administration have already happened.
That pattern is one of the most common root causes in prolonged antimicrobial and OPAT billing.
This scenario applies to:
- Prolonged antimicrobial therapy requiring reauthorization mid-course
- OPAT services spanning home, infusion suite, or facility settings
- Infusion administration with separate drug-specific authorization rules
- Specialty medications under medical, rather than pharmacy, benefit
Clinical notes, culture and susceptibility findings, treatment history, dose and route rationale, and monitoring documentation often support medical necessity, but only when they map to the payer's specific policy criteria.
IDSA's OPAT guideline places indication, antimicrobial selection, and duration decisions with the treating physician, but clinical judgment and a payer's coverage determination are two different things. Appeals land better when they cite the specific coverage criterion met, not a general medical-necessity argument.
Coding, Claim Construction, and Documentation Denials
ID encounters frequently involve multiple related services on one date, which multiplies the places a claim can go wrong:
- Diagnosis-to-procedure mismatches
- E/M levels unsupported by documentation
- Incorrect or missing modifiers
- Place-of-service errors
- Wrong units, dates, or drug details (including NDC where required)
The claim has to represent exactly what happened, who performed it, where, and when. Validate current ICD-10-CM, CPT, HCPCS, and modifier requirements against authoritative payer resources rather than relying on how your practice has always billed a code.
OPAT, Infusion, Drug, and Facility-Professional Coordination Denials
OPAT and infusion billing often spans several components: professional services, facility charges, the drug itself, administration, nursing, and lab monitoring. Each can be billed by a different party, on a slightly different date, in a different location.
That's where coordination denials come from. Watch for:
- Inconsistent dates or units between professional and facility claims
- Start and stop times missing from infusion documentation
- Drug units billed that don't match administered-plus-discarded quantities
- Confusion over which services are bundled versus separately payable
Billing units matter more than most practices realize. CMS's infusion coding rules generally allow one initial service per encounter, with separate IV access sites as the main exception. Drug wastage has its own reporting requirement: separately payable single-dose drugs need administered and discarded amounts split onto separate claim lines.
Before calling anything "separately billable," confirm current payer policy and contract language. Bundling rules change, and assuming last year's answer still applies is a reliable way to generate a denial.
Partial-Payment, Underpayment, and Aging-Related Scenarios
Not every problem is a flat denial. A claim can get a partial payment, an unexpected adjustment, or misassigned patient responsibility — and still be financially unresolved.
Compare four things on every questionable remittance:
- The allowed amount versus your contracted rate
- The contractual adjustment applied
- The actual payment received
- The denial reason or remark code tied to any shortfall
In buy-and-bill drug billing, a hard denial isn't deferred revenue waiting to be collected later. It's a realized loss on inventory you already purchased and administered. That distinction should drive how aggressively you escalate it.
Prioritize escalation using:
- Timely-filing and appeal deadlines
- Dollar value (rank by dollars, not claim count)
- Clinical complexity
- Likelihood of successful correction
A count-sorted denial report will bury a $4,000 denied infusion claim under twenty $40 office-visit rejections. Dollar-based ranking fixes that.
How to Respond to and Prevent A/R Denials
Once a denial lands, the response should follow a consistent path rather than getting worked ad hoc by whoever has time that day.
A Denial-Triage Workflow That Actually Holds Up
- Capture the payer message and deadline: include the exact denial code and appeal window
- Classify the root cause: eligibility, authorization, coding, medical necessity, or coordination
- Decide: correct or appeal: submit a corrected claim only if the underlying data was wrong; use reconsideration or appeal when the original claim was accurate
- Assign ownership and a next action: no denial should sit without a named person and a date
Before resubmitting anything, pull the full claim record:
- Registration data and eligibility response
- Authorization, referral, and charge capture
- Codes, modifiers, units, and place of service
- Clinical documentation, attachments, and the remittance advice
Skipping this step is how practices resubmit the same broken claim twice.
Building Prevention Into the Workflow
Fixing a denial after the fact is reactive. The bigger wins come from stopping the same denial from recurring:
- Build payer-specific checks for authorization expiration dates, flagged early enough to file reauthorization before a course lapses
- Verify provider enrollment covers every site and service (office, infusion suite, and OPAT) before claims go out
- Maintain a one-page reference per drug per payer: authorization requirement, clinical criteria, submission channel, expected turnaround
- Track denial performance by payer, provider, code family, service line, aging bucket, and appeal outcome
MGMA's denial framework recommends focusing corrective effort on whichever root cause carries the biggest revenue-cycle impact, not whichever denial is easiest to fix. For an ID practice, that's almost always authorization lapses and drug-coordination errors, simply because of the dollar amounts involved.
For practices that want more depth before building internal processes, GrowInfectiousDisease publishes free, ungated guides and calculators on infectious disease revenue cycle, OPAT economics, and denial patterns. They are built for physicians and administrators to apply against their own practice numbers, not as a substitute for working actual claims.
Periodic denial huddles that pull in clinical, coding, front-office, authorization, and billing staff catch recurring causes at the source instead of re-working the same issue in AR every month.
What to Check Before Finalizing a Denial Workflow
A few sanity checks before you lock in a process:
- Coding is rarely the only cause. Verify eligibility, authorization, payer policy, documentation, provider enrollment, and contract payment terms first.
- Balance size is not the only priority. Weigh appeal deadlines, timely-filing risk, repeat frequency, and whether a denial signals a systemic failure.
- Rules from other specialties often fail in ID. Confirm current, payer-specific U.S. guidance and document which requirements are payer-specific versus practice-specific.
- Confirm the basics are in place: a clear escalation path, secure record access, consistent denial-status definitions, and a feedback loop back into registration, authorization, and coding.
A queue with one named owner, a backup, and a daily review of anything past target beats a shared inbox every time.
Conclusion
Most AR denials in infectious disease billing aren't random. They're symptoms of disconnected eligibility checks, authorization tracking, documentation, coding, and payment-posting processes that don't talk to each other.
Categorizing denials by root cause, responding according to deadline and dollar value, and feeding what you learn back into your own workflow (using your practice's own data rather than generic benchmarks) is what actually improves collections.
Frequently Asked Questions
What is an A/R denial in medical billing?
An A/R denial is an unpaid, underpaid, or payer-rejected balance that sits in accounts receivable after the payer reviews a submitted claim. It requires correction, follow-up, reconsideration, or appeal before the balance can resolve.
What are the most common denial reasons for infectious disease practices?
Eligibility and coordination-of-benefits gaps, expired or missing authorization, coding and documentation mismatches, medical-necessity disputes, and provider enrollment or place-of-service errors all show up regularly. Which one dominates depends on your payer mix and service lines.
How do OPAT and infusion services create medical billing denials?
These services involve multiple billable components : professional, facility, drug, administration, and lab — often across different locations and providers. When dates, units, or documentation don't align across those pieces, denials follow.
